Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) has been given an average recommendation of "Hold" by the twelve analysts that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $17.90.
Several research analysts recently commented on DCPH shares. Piper Sandler raised their price target on shares of Deciphera Pharmaceuticals from $13.00 to $18.00 in a research note on Sunday, September 11th. HC Wainwright increased their target price on shares of Deciphera Pharmaceuticals from $20.00 to $25.00 and gave the stock a "buy" rating in a report on Monday, September 12th. SVB Leerink raised their price target on shares of Deciphera Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a report on Monday, September 12th. JMP Securities upgraded shares of Deciphera Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $23.00 target price for the company in a research note on Friday, August 5th. Finally, Cowen began coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, August 29th. They issued an "outperform" rating and a $25.00 target price for the company.
Get Deciphera Pharmaceuticals alerts:Deciphera Pharmaceuticals Stock Performance
Shares of NASDAQ:DCPH opened at $18.10 on Friday. The firm has a fifty day moving average price of $15.97 and a 200 day moving average price of $12.63. Deciphera Pharmaceuticals has a fifty-two week low of $6.51 and a fifty-two week high of $20.88. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -4.23 and a beta of 1.00.
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last issued its earnings results on Thursday, August 4th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.05. Deciphera Pharmaceuticals had a negative net margin of 231.99% and a negative return on equity of 74.37%. The firm had revenue of $32.49 million during the quarter, compared to analyst estimates of $30.11 million. During the same quarter in the prior year, the business earned ($1.21) earnings per share. Deciphera Pharmaceuticals's revenue for the quarter was up 37.8% on a year-over-year basis. As a group, research analysts predict that Deciphera Pharmaceuticals will post -2.5 earnings per share for the current year.Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the company. Northern Trust Corp boosted its holdings in Deciphera Pharmaceuticals by 2.4% in the fourth quarter. Northern Trust Corp now owns 410,700 shares of the company's stock valued at $4,013,000 after purchasing an additional 9,740 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Deciphera Pharmaceuticals by 36.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 297,545 shares of the company's stock worth $2,907,000 after acquiring an additional 79,192 shares in the last quarter. BNP Paribas Arbitrage SA raised its position in Deciphera Pharmaceuticals by 29.5% in the fourth quarter. BNP Paribas Arbitrage SA now owns 20,140 shares of the company's stock worth $197,000 after acquiring an additional 4,588 shares in the last quarter. Ensign Peak Advisors Inc purchased a new position in Deciphera Pharmaceuticals in the fourth quarter worth $373,000. Finally, Goldman Sachs Group Inc. raised its position in Deciphera Pharmaceuticals by 739.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,635,510 shares of the company's stock worth $35,519,000 after acquiring an additional 3,202,527 shares in the last quarter. Institutional investors and hedge funds own 72.29% of the company's stock.
About Deciphera Pharmaceuticals
(Get Rating)
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
See Also
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.